vs
PROSPERITY BANCSHARES INC（PB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
PROSPERITY BANCSHARES INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.8倍（$367.6M vs $207.3M），PROSPERITY BANCSHARES INC净利率更高（31.6% vs -62.0%，领先93.6%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 19.2%）
Prosperity Bancshares Inc.是总部位于美国得克萨斯州休斯顿的银行控股公司，业务覆盖得克萨斯州及俄克拉荷马州中部。截至2019年12月31日，公司共运营285家分支机构，广泛分布在休斯顿、达拉斯-沃斯堡都会区及得州南部、东部、中部、西部等区域。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PB vs RARE — 直观对比
营收规模更大
PB
是对方的1.8倍
$207.3M
净利率更高
PB
高出93.6%
-62.0%
两年增速更快
RARE
近两年复合增速
19.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $367.6M | $207.3M |
| 净利润 | $116.3M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 31.6% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | -10.7% | 3.5% |
| 每股收益（稀释后） | $1.16 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBRARE
| Q1 26 | $367.6M | — | ||
| Q4 25 | $275.0M | $207.3M | ||
| Q3 25 | $273.4M | $159.9M | ||
| Q2 25 | $267.7M | $166.5M | ||
| Q1 25 | $265.4M | $139.3M | ||
| Q4 24 | $267.8M | $164.6M | ||
| Q3 24 | $261.7M | $139.5M | ||
| Q2 24 | $258.8M | $147.0M |
净利润PBRARE
| Q1 26 | $116.3M | — | ||
| Q4 25 | $139.9M | $-128.6M | ||
| Q3 25 | $137.6M | $-180.4M | ||
| Q2 25 | $135.2M | $-115.0M | ||
| Q1 25 | $130.2M | $-151.1M | ||
| Q4 24 | $130.1M | $-133.2M | ||
| Q3 24 | $127.3M | $-133.5M | ||
| Q2 24 | $111.6M | $-131.6M |
营业利润率PBRARE
| Q1 26 | — | — | ||
| Q4 25 | 65.1% | -54.7% | ||
| Q3 25 | 64.4% | -106.9% | ||
| Q2 25 | 64.3% | -64.8% | ||
| Q1 25 | 62.7% | -102.6% | ||
| Q4 24 | 62.0% | -74.3% | ||
| Q3 24 | 62.1% | -94.6% | ||
| Q2 24 | 55.2% | -79.1% |
净利率PBRARE
| Q1 26 | 31.6% | — | ||
| Q4 25 | 50.9% | -62.0% | ||
| Q3 25 | 50.3% | -112.8% | ||
| Q2 25 | 50.5% | -69.0% | ||
| Q1 25 | 49.1% | -108.5% | ||
| Q4 24 | 48.6% | -80.9% | ||
| Q3 24 | 48.6% | -95.7% | ||
| Q2 24 | 43.1% | -89.5% |
每股收益（稀释后）PBRARE
| Q1 26 | $1.16 | — | ||
| Q4 25 | $1.48 | $-1.28 | ||
| Q3 25 | $1.45 | $-1.81 | ||
| Q2 25 | $1.42 | $-1.17 | ||
| Q1 25 | $1.37 | $-1.57 | ||
| Q4 24 | $1.36 | $-1.34 | ||
| Q3 24 | $1.34 | $-1.40 | ||
| Q2 24 | $1.17 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.2B | $-80.0M |
| 总资产 | $43.6B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PBRARE
| Q1 26 | — | — | ||
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M |
股东权益PBRARE
| Q1 26 | $8.2B | — | ||
| Q4 25 | $7.6B | $-80.0M | ||
| Q3 25 | $7.7B | $9.2M | ||
| Q2 25 | $7.6B | $151.3M | ||
| Q1 25 | $7.5B | $144.2M | ||
| Q4 24 | $7.4B | $255.0M | ||
| Q3 24 | $7.4B | $346.8M | ||
| Q2 24 | $7.3B | $432.4M |
总资产PBRARE
| Q1 26 | $43.6B | — | ||
| Q4 25 | $38.5B | $1.5B | ||
| Q3 25 | $38.3B | $1.2B | ||
| Q2 25 | $38.4B | $1.3B | ||
| Q1 25 | $38.8B | $1.3B | ||
| Q4 24 | $39.6B | $1.5B | ||
| Q3 24 | $40.1B | $1.5B | ||
| Q2 24 | $39.8B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流PBRARE
| Q1 26 | — | — | ||
| Q4 25 | $78.3M | $-99.8M | ||
| Q3 25 | $194.8M | $-91.4M | ||
| Q2 25 | $98.2M | $-108.3M | ||
| Q1 25 | $178.2M | $-166.5M | ||
| Q4 24 | $-205.8M | $-79.3M | ||
| Q3 24 | $274.6M | $-67.0M | ||
| Q2 24 | $216.5M | $-77.0M |
自由现金流PBRARE
| Q1 26 | — | — | ||
| Q4 25 | $68.5M | $-100.8M | ||
| Q3 25 | $185.7M | $-92.7M | ||
| Q2 25 | $91.8M | $-110.7M | ||
| Q1 25 | $171.1M | $-167.8M | ||
| Q4 24 | $-210.7M | $-79.5M | ||
| Q3 24 | $270.2M | $-68.6M | ||
| Q2 24 | $211.8M | $-79.0M |
自由现金流率PBRARE
| Q1 26 | — | — | ||
| Q4 25 | 24.9% | -48.6% | ||
| Q3 25 | 67.9% | -58.0% | ||
| Q2 25 | 34.3% | -66.5% | ||
| Q1 25 | 64.5% | -120.5% | ||
| Q4 24 | -78.7% | -48.3% | ||
| Q3 24 | 103.3% | -49.2% | ||
| Q2 24 | 81.8% | -53.7% |
资本支出强度PBRARE
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 0.5% | ||
| Q3 25 | 3.3% | 0.8% | ||
| Q2 25 | 2.4% | 1.5% | ||
| Q1 25 | 2.7% | 1.0% | ||
| Q4 24 | 1.8% | 0.1% | ||
| Q3 24 | 1.7% | 1.2% | ||
| Q2 24 | 1.8% | 1.4% |
现金转化率PBRARE
| Q1 26 | — | — | ||
| Q4 25 | 0.56× | — | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | -1.58× | — | ||
| Q3 24 | 2.16× | — | ||
| Q2 24 | 1.94× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
